Introduction
============

Cerebral ischemia reperfusion is one of the effective measures for the treatment of stroke; however, during cerebral ischemia/reperfusion (I/R), a large number of inflammatory factors are released from local ischemic tissue ([@b1-mmr-19-03-1443]). These activated inflammatory cells can infiltrate local tissue, and activate the relevant inflammatory signaling pathway, such as the TLR4/NF-κB signaling pathway, thereby resulting in severe inflammatory injury ([@b2-mmr-19-03-1443],[@b3-mmr-19-03-1443]). A recent study has demonstrated that I/R injury is accompanied with apoptosis ([@b4-mmr-19-03-1443]), and apoptosis can increase with prolonged durations of ischemia ([@b5-mmr-19-03-1443]). Therefore, the effects of apoptosis in I/R injury require further investigation.

Cerebral ischemia/hypoxia-induced neuronal apoptosis is regulated by the phosphoinositide 3-kinase (PI3K)/serine/threonine protein kinase Akt pathway ([@b6-mmr-19-03-1443]). Forkhead box O1 (FoxO1) is a downstream molecule of the P13K/Akt pathway ([@b7-mmr-19-03-1443]). The PI3K/Akt/FoxO1 signaling pathway is a classical pathway that mediates cell survival, serves an important role in I/R injury in the brain, intestine and liver, and is associated with inflammatory response and apoptosis ([@b8-mmr-19-03-1443]--[@b10-mmr-19-03-1443]).

Lipopolysaccharide (LPS) is a major component of the gram-negative bacteria cytoderm, which regulates inflammation and the immune system by activating the relevant receptor-mediated signaling pathway ([@b11-mmr-19-03-1443]). Zhou *et al* ([@b12-mmr-19-03-1443]) demonstrated that LPS induced PI3K/Akt phosphorylation as well as NF-κB activation and induced acute lung injury. High doses of LPS induce a strong inflammatory response, leading to fatal sepsis or septic shock; while low-dose LPS can induce a protective cross-tolerance state ([@b13-mmr-19-03-1443]). One form of stimulus-induced tolerance leads to different types of injuries, including ischemia-reperfusion and trauma; however, autoimmune injury can exhibit protective effects ([@b14-mmr-19-03-1443],[@b15-mmr-19-03-1443]). Gong *et al* ([@b16-mmr-19-03-1443]) demonstrated that in cerebral ischemic injury rats models, the neuroprotective effect of LPS pretreatment may occur via the regulation of inflammatory mediators, the induction of neuroprotective factors and the inhibition of proinflammatory cytokine release. The present study sought to investigate the effects of low-dose LPS on brain injury in cerebral I/R rats and on the protein expression of PI3K/AKT/FoxO1 pathway in rat models of cerebral I/R injury, and to investigate the protective effect of low-dose LPS against brain injury and its molecular mechanism, so as to provide evidence for treating cerebral I/R injury.

Materials and methods
=====================

### Animals and ethics approval

A total of 30 male Sprague-Dawley rats weighing 260--280 g, aged 8 weeks, were obtained from Shenyang Military Region General Hospital Laboratory Animal Center \[Shenyang, China; license No. SCXK (JUN) 2012\--0002\]. Animals were housed at a constant temperature (22±1°C), with 50% relative humidity, and a 12-h light/dark cycle. The rats had *ad libitum* access to food and autoclaved water. All animal procedures were approved by the Animal Experiments Ethics Committee of the General Hospital of Shenyang Military Region (Shenyang, China). Rats were randomly divided into three groups: The control group (control group; n=10), intraperitoneal injection of saline for 3 days, 0.2 mg/kg, 1 time/day; cerebral I/R group (I/R group; n=10), established cerebral I/R injury model; LPS pretreatment (n=10), intraperitoneal injection of LPS (*Escherichia coli* 0128:B12, L2887, Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) dissolved in saline, 0.2 mg/kg 3 days before I/R (once a day).

### Cells and groups

HAPI rat microglial cells were purchased from Bena Culture Collection (Jiangsu, China; cat. no. BNCC340723). Microglia were divided into the control group, I/R group, LPS+I/R group (LPS group) and PI3K inhibitor+LPS+I/R group (LY group). In the I/R group, I/R was simulated by hypoxia and reoxygenation; in the LPS group, LPS was administered prior to hypoxia and during reoxygenation; and, in the PI3K group, both LPS and PI3K inhibitor LY294002 (2.5 µg/kg; cat. no. B-0294; Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) were added prior to hypoxia and during reoxygenation.

### Preparation of cerebral I/R injury model in rats

Animal models were prepared in accordance with a previous method ([@b17-mmr-19-03-1443]). Rats were intraperitoneally anesthetized with 40 mg/kg sodium pentobarbital. The right pterygopalatine artery and external carotid artery were ligated. A small cut was made on the external carotid artery by a syringe needle \~0.5 cm from the ligation site. Then a nylon bolt was pushed into the internal carotid artery in the direction of the skull through the right external carotid artery incision. Common carotid artery bifurcation was taken as a marker and the nylon bolt pushed there. The middle cerebral artery was blocked when a slight resistance was felt in the depth of 18--20 mm. After blocking for 2 h, the nylon thread was pulled out and the arterial stump was fastened securely; subcutaneous tissue and skin were sutured. In this way, cerebral I/R injury models were successfully established.

### Establishment of hypoxia-reoxygenation model

A hypoxic solution was used to simulate the I/R injury process in microglia. The hypoxic solution consisted of NaCl 137 mM, KCl 12 mM, MgCl~2~ 0.49 mM, CaCl~2~−2H~2~O 0.9 mM, HEPES 4 mM, deoxyglucose 10 mM, sodium sulfite 0.75 mM and sodium lactate 20 mM, pH 6.5. During the hypoxia procedure, the cells were placed in 95% N~2~ and 5% CO~2~ for 2 h. During the reoxygenation process, cells were placed in normal culture medium (89% DMEM+10% FBS+1% resistance) and incubated for 4 h at 37°C. The LPS group was administered 100 ng/ml LPS (0.2 mg/kg) for 3 days; LPS was administered again prior to hypoxia and during reoxygenation at 37°C. In the PI3K group, both LPS and PI3K inhibitor LY294002 were added prior to hypoxia for 2 h and during reoxygenation for 4 h at 37°C.

### Neurological function score and changes in rat hemodynamics

Neurological function scores of rats in each group were assessed according to the Longa score scale ([@b18-mmr-19-03-1443]). Longa scoring criteria were: 0, no evident neurological deficit; 1, left limb can flex but cannot extend when lifting the tails (mild); 2, unilateral circling, animals can maintain balance at resting state (moderate); 3, animals are unstable and incline to contralateral side at resting state (severe); and 4, no visible activity (extremely severe). The hemodynamics (rectal temperature, pH, PaCO~2~, PaO~2~ and hemoglobin) were detected by the Datex-Ohmeda S/5 Entropy Module (Datex-Ohmeda Division, Instrumentarium Corp., Helsinki, Finland).

### Specimen collection and processing

Arterial and venous blood samples were collected at 6 h after I/R; the rats were sacrificed by administration of an overdose of sodium pentobarbital. Then, the brain tissue was isolated from the rats of each group; 4 of the rats were used for triphenyl tetrazolium chloride (TTC) staining, 3 of them were fixed in 4% paraformaldehyde for 48 h at room temperature, and the other 3 were stored at −80°C for western blotting and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The serum was obtained by centrifugation at 1,000 × g for 10 min at 4°C, and stored at −80°C.

### TTC staining and infarct volume measurement

The brain tissues from 4 rats of each group were frozen at −20°C for 20 min. Each brain tissue was cut into 2 mm thick brain slices from the front to the rear with a rat brain slice mold, obtaining a total of 4 pieces. The brain tissues were transferred to a Petri dish containing 4% TTC solution, stained at 37 °C in the dark for 30 min and fixed with 4% paraformaldehyde solution at room temperature for 10 min. In accordance with the method proposed by Swanson, the region of non-infarcted area on the infarct side and the area contralateral to the infarct of each brain slice were measured ([@b19-mmr-19-03-1443]). Infarct volume was expressed as the percentage of the infarct volume to total contralateral volume: Contralateral infarct volume-the volume of non-infarcted area on the infarct side)/contralateral infarct volume ×100%.

### Histopathological changes

Brain tissues were harvested and fixed in 4% paraformaldehyde for 48 h at room temperature. After 48 h, specimens were dehydrated with 70, 80, 90, 95 and 100% ethanol, followed by clearing in xylene, embedding in paraffin and sectioning (5-µm-thick sections). Sections were deparaffinized, transferred to xylene, rehydrated with a graded ethanol series, stained with hematoxylin for 3 min, differentiated with 0.3% hydrochloric acid for 30 sec, diluted with aqueous ammonia for 1 min and counterstained with 0.5% eosin solution for 1 min, all at room temperature. Sections were washed with distilled water after each step. Following staining, sections were dehydrated, rinsed, cleared in xylene, mounted, and the pathological changes of brain tissue were observed under a light microscope (5 fields were randomly selected; magnification, ×200).

### Terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling (TUNEL) staining

The apoptosis of brain tissues was detected according to the protocols of the TUNEL kit (In situ cell death detection kit-POD; cat. no. 11684817910; Roche Diagnostics GmbH, Mannheim, Germany). Brain tissues were dehydrated, embedded, sectioned (5-µm-thick sections) and incubated with 0.9% NaCl for 5 min at room temperature, then rinsed twice with PBS, mixed with biotinylated nucleotides and terminal deoxynucleotidyl transferase, covered with plastic coverslips and incubated at 37°C for 60 min. Following the addition of 50 µl of TUNEL reaction mixture, samples were incubated for 60 min at 37°C in a humidified atmosphere in the dark. Following rinsing of the slides three times in PBS for 5 min each, samples were analyzed in a drop of PBS under a fluorescence microscope (5 fields were randomly selected; magnification, ×200).

### Annexin V/propidium iodide (PI) staining

The Annexin V-PI (cat. no. BD 556547; BD Biosciences, Franklin Lakes, NJ, USA) method was used to detect the apoptosis rate (apoptosis rate=early apoptosis rate+late apoptosis rate) of microglia by flow cytometry. Cells were harvested with 0.05% trypsin (10 min at room temperature), washed three times with cold PBS (4°C), and collected by centrifugation at 180 × g for 5 min at 4°C. Then, cells were resuspended in 200 µl binding buffer and incubated with Annexin V (10 µg/ml) and PI (10 µg/ml) in the dark for 15 min at room temperature. The cells were detected using a flow cytometer (BD Biosciences). Data were analyzed using FlowJo version 10 software (FlowJo LLC, Ashland, OR, USA).

### MTT assay

The cells in logarithmic growth phase were inoculated into 96-well culture plates at a density of 2,000--5,000 per well and 100 µl cells per well. MTT solution (5 mg/ml) 20 µl was added to each well and the cells cultured for an additional 4 h at 37°C. Then the supernatant was removed and 150 µl DMSO was added per well. Cells were agitated for 10 min and the crystals fully dissolved. The optical density (OD) was measured at 570 nm with plate reader (Infinite 200 PRO, Tecan Group, Ltd., Mannedorf, Switzerland), and the cell survival rate was calculated and inhibition was investigated. Cell survival rate=(OD value of the intervention group/OD value of the normal control group) ×100.

### Western blotting

The samples were ground and centrifuged in a pre-chilled RIPA Lysis Buffer (cat. no. P0013B; Beyotime Institute of Biotechnology) at 14,000 × g for 30 min at 4°C. Protein concentration was determined using a BCA protein assay kit (23227; Thermo Fisher Scientific, Inc.). The supernatant of total protein (40 µg) was extracted for 10% SDS-polyacrylamide gel electrophoresis and the protein was semi-dried for PVDF membrane transfer. The membranes were blocked with 5% skim milk powder for 2 h at room temperature and incubated overnight at 4°C with B-cell lymphoma 2 (Bcl-2; 1:1,000; cat. no. ab59348; Abcam, Cambridge, MA, USA), Bcl-2-associated X (Bax; 1:2,000; cat. no. ab32503; Abcam), caspase-3 (1:500 dilutions; cat. no. ab13847; Abcam), Akt (1:10,000; cat. no. ab179463; Abcam), FoxO1 (1:1,000 dilutions; cat. no. ab52857; Abcam), phosphorylated (p)-Akt (1:1,000 dilutions; cat. no. ab131443; Abcam) and p-FoxO1 (1:1,000; cat. no. ab131339; Abcam) antibodies. All the antibodies were diluted with antibody dilution buffer (cat. no. A1820; Beijing Solarbio Science & Technology Co., Ltd.) followed by three washes and incubation with secondary antibody (goat anti-rabbit IgG/HRP antibody; 1:5,000; cat. no. ab6721; Abcam) for 1 h at room temperature. After four washes using TBST, cells were developed with ECL luminescence kit (32109; Thermo Fisher Scientific, Inc.) and gel imaging system, gray value was measured by using Quantity One software (version 4.6.8, Bio-Rad Laboratories, Inc., Hercules, CA, USA).

### RT-qPCR

Primers were designed according to the sequences of Bax, Bcl-2 and caspase3 as reported in GenBank (<https://www.ncbi.nlm.nih.gov/genbank/>), and were synthesized by Sangon Biotech (Shanghai) Co., Ltd. (Shanghai, China). Total RNA was isolated with TRIzol reagent (cat. no. 15596018; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), RNA purity and quantification were tested by NanoDrop One Microvolume UV-Vis Spectrophotometer (cat. no. ND-ONE-W; Thermo Fisher Scientific, Inc.). Reversely transcribed into cDNA using 5X PrimeScript RT Master Mix 2 µl (RR036A, Takara Biotechnology Co., Ltd., Dalian, China) and 8 µl total RNA. The RT reaction was conducted at: 37°C for 15 min and then at 85°C for 5 sec. cDNA was then stored at 4°C until use. A SYBR Premix Ex Taq kit (cat. no. RR820A; Takara Biotechnology Co., Ltd., Dalian, China) was used for the detection according to the manufacturer\'s protocols. Initial denaturation at 95°C for 30 sec; 40 cycles of 95°C for 5 sec and 60°C for 30 sec. The relative gene expression data was analyzed with the 2^−∆∆Cq^ method ([@b20-mmr-19-03-1443]). The primers used for qPCR were: Bax forward, 5′-GTGGATACAGACTCCCCC-3′, reverse, 5′-AGCGGCTGTTTGTCTGGA-3′; Bcl-2 forward, 5′-TGATAACCGGGAGATCGTGA-3′, reverse, 5′-TCTCTGAAGACGCTGCTCAG3′; caspase-3 forward, 5′-TGAATGGAAACAACCAGT3′, reverse 5′-TCAAGCACCTGACCCTTA3′; and GAPDH forward, 5′-AACTTTGGCATTGTGGAAGG3′ and reverse 5′-CACATTGGGGGTAGGAACAC3′. The experiments were replicated three times.

### Statistical analysis

Data were analyzed using SPSS version 19.0 statistical software (IBM Corp., Armonk, NY, USA) and measurement data were expressed as mean ± standard deviation. Comparisons between groups were made using the Student\'s t-test (two-tailed) or one-way analysis of variance with Tukey\'s post-test analysis. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Establishment of I/R model in rats and identification of infarct area

All rats were conscious for 60--90 min following anesthesia. Rats in the control group did not show evident neurological deficits. Rats in the I/R group had different degrees of neurological abnormalities. Compared with the control group, neurological deficit scores significantly increased following I/R (P\<0.05; [Fig. 1A](#f1-mmr-19-03-1443){ref-type="fig"}). In the I/R group, rectal temperature, pH and arterial blood carbon dioxide partial pressure (PaCO~2~) were stable; however, oxygen partial pressure (PaO~2~) and hemoglobin was significantly decreased compared with the control ([Fig. 1B](#f1-mmr-19-03-1443){ref-type="fig"}). TTC staining demonstrated that the structure of the brain was normal in the control group; In the IR group, an evident infarct area was demonstrated, compared with the control group, the infarct volume was significant increased (P\<0.05); the LPS group possessed an evident infarct area, compared with the IR group, the infarct volume was significant decreased. (P\<0.05; [Fig. 1C](#f1-mmr-19-03-1443){ref-type="fig"}). These results suggested that the I/R model had been successfully established.

### LPS protects I/R injury in rats

To determine the effect of LPS treatment following I/R injury, it was observed by hematoxylin and eosin staining that neuronal cells were arranged orderly in the control group, with clear boundaries and intact nuclei ([Fig. 2A](#f2-mmr-19-03-1443){ref-type="fig"}). Neuronal cells in the I/R group were disorderly, with unclear boundaries, myofiber rupture and fewer visible nuclei. The rats or the I/R group also found it difficult to maintain balance in a docile state (data not shown). In the LPS group, brain tissue injury was improved and the severity was alleviated compared with the I/R group; the neurological scores were reduced and every limb extended freely ([Fig. 2B](#f2-mmr-19-03-1443){ref-type="fig"}). These data indicated that LPS significantly attenuated brain tissue injury following I/R injury.

### LPS protects brain tissue from I/R injury-induced apoptosis

To the effects of LPS on apoptosis following I/R injury were analyzed. It was observed that the number of TUNEL-positive cells had markedly increased in the I/R group compared with the control and that apoptotic cells had markedly decreased following LPS intervention ([Fig. 3A](#f3-mmr-19-03-1443){ref-type="fig"}). Next, the expression of apoptosis-related proteins and mRNA were examined. The expression of Bax and caspase-3 in brain tissue was significantly higher, while Bcl-2 expression was significantly lower in the I/R group compared with in the control group (P\<0.05). Following LPS intervention, Bax and caspase-3 expression was significantly decreased and Bcl-2 protein had increased compared with the I/R group ([Fig. 3B and C](#f3-mmr-19-03-1443){ref-type="fig"}). These results demonstrated that LPS treatment reduces neuronal cells apoptosis induced by cerebral I/R injury.

### LPS inhibits neuronal apoptosis via the PI3K/Akt/FoxO1 signaling pathway following I/R injury

To ascertain whether the PI3K/Akt/FOXO1 signaling pathway mediated neuronal apoptosis, the expression levels of several key factors in the signaling pathway were detected *in vitro* and *in vivo*. In the I/R group, PI3K, Akt and p-Akt expression increased, whereas FoxO1 and p-FoxO1 expression was significantly reduced compared with the control. LPS treatment significantly reversed the expression levels of these proteins toward normal levels in rats compared with the I/R group ([Fig. 4A and B](#f4-mmr-19-03-1443){ref-type="fig"}). These results suggested that protection of LPS against I/R injury induced cell apoptosis and may be mediated through the PI3K/Akt/FoxO1 signaling pathway. To further verify the mechanism, the cell viability in each group was detected with an MTT assay following reoxygenation. LPS treatment significantly enhanced the viability of microglia following hypoxia/reoxygenation compared with the I/R group (P\<0.05; [Fig. 4C](#f4-mmr-19-03-1443){ref-type="fig"}).

The apoptotic rate of the I/R group was 24.65% and that of the LPS group was 17.67%. There was a significant difference between the I/R and LPS groups (P\<0.05). In addition, LY294002, a PI3K pathway inhibitor, was used. The PI3K inhibitor was added to the LPS group, and the apoptotic rate was 23.55% (P\<0.05; [Fig. 4D and E](#f4-mmr-19-03-1443){ref-type="fig"}); a significant difference was observed compared with the LPS group. Akt was phosphorylated to p-Akt in the LPS group, the expression was increased, FoxO1 was inactivated and the expression of p-FoxO1 decreased, which was statistically different compared with the I/R group (P\<0.05). Following the addition of PI3K inhibitor, the role of LPS was inhibited, as the levels of p-Akt and p-FoxO1 were significantly decreased and increased, respectively ([Fig. 4F and G](#f4-mmr-19-03-1443){ref-type="fig"}). The data indicated that low-dose LPS can reduce I/R-induced brain injury and prevent brain injury through the PI3K/Akt/FOXO1 signaling pathway.

Discussion
==========

Ischemic stroke is the second most common type critical disease worldwide and leads to mortality and permanent dysfunction, including cricopharyngeal dysfunction ([@b21-mmr-19-03-1443],[@b22-mmr-19-03-1443]). Brain injury induced by cerebral ischemia is the cause of exacerbations and damage mechanisms, including inflammatory response, oxidative stress, apoptosis and mitochondrial dysfunction ([@b23-mmr-19-03-1443]--[@b26-mmr-19-03-1443]). With immediate ischemia and reperfusion, a large number of inflammatory factors and oxygen free radicals are released, caused by the infiltration of inflammatory cells and neutrophil degranulation, while the formation of apoptotic bodies is stimulated ([@b27-mmr-19-03-1443],[@b28-mmr-19-03-1443]). The present study observed the effects of low-dose LPS on I/R-induced brain injury, and the results demonstrated that low-dose LPS suppressed I/R-induced morphological changes, decreased inflammatory factor expression and diminished apoptosis. The results also demonstrated that LPS decreased I/R-induced protein expression of PI3K/Akt/FoxO1 pathway and suggested that low-dose LPS relieved brain injury following I/R injury, possibly through the PI3K/Akt/FoxO1 pathway.

LPS as a small molecule material, can pass through the blood-brain barrier and gathers in the central nervous system ([@b29-mmr-19-03-1443]). Low-dose LPS can induce the body to exhibit cross-immune tolerance, serving a protective effect on brain injury ([@b30-mmr-19-03-1443]). The present study reported that LPS can significantly enhance the tolerance against cerebral I/R injury and protect against subarachnoid hemorrhage and may improve the prognosis of neurological function. Rosenzweig *et al* ([@b31-mmr-19-03-1443]) demonstrated that pretreatment with 0.2 mg/kg LPS significantly reduced the cerebral ischemic inflammatory response. Ding and Li ([@b32-mmr-19-03-1443]) identified that low-dose LPS pretreatment can reduce the production of pro-inflammatory cytokines, including tumor necrosis factor α, and reduce glial cell inflammatory injury. In the present study, a rat model of cerebral I/R was established. Following low-dose LPS pretreatment, injury to the brain tissue was reduced, suggesting that low-dose LPS can inhibit the inflammatory response in cerebral I/R.

In the process of cerebral I/R, an abnormal interaction occurs among inflammatory, vascular endothelial and nerve cells, and a large number of soluble inflammatory factors are released, which. mediate apoptosis-induced intracellular calcium overload ([@b33-mmr-19-03-1443]). In the early stage of reperfusion, neutrophils and vascular endothelial cells release chemokines, leading to vascular dysfunction, tissue injury and finally apoptosis is induced. To further observe the effect of low-dose LPS on the apoptosis of I/R injury, TUNEL was used to detect the apoptosis of neurons in the cortical ischemic area. The results of the present study revealed that the apoptosis of microglia of the I/R group was significantly higher compared with the control and LPS groups, while the LPS group exhibited significantly fewer apoptotic cells compared with the I/R group. Furthermore, low-dose LPS could significantly reduce Bax and caspase-3 expression levels following I/R injury, indicating that low-dose LPS exerted protective effects against cerebral I/R injury in rats via an anti-apoptotic mechanism.

Previous studies have demonstrated that the PI3K/AKT signaling pathways are involved in neuronal apoptosis in cerebral ischemia ([@b34-mmr-19-03-1443]--[@b36-mmr-19-03-1443]). The activation of the intrinsic pathway and external inflammatory can drive the AKT-mediated cell survival pathway, activate PI3K, connect the intracellular C-terminal of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, activate its downstream kinase Akt (Ser473) residue phosphorylation and induce the downstream protein FoxO1 to the cell membrane translocation ([@b37-mmr-19-03-1443],[@b38-mmr-19-03-1443]). Phosphorylation of Ser9 causes FoxO1 inactivation and phosphorylated β-catenin promotes cell survival ([@b39-mmr-19-03-1443],[@b40-mmr-19-03-1443]). The results of the present study demonstrated that low-dose LPS treatment significantly reduced the apoptotic rate in rats following I/R or in cells following hypoxia/reoxygenation. The PI3K/Akt/FoxO1 signaling pathway serves an important role. Low-dose LPS in the I/R model can be used to activate PI3K and AKT phosphorylation, increase p-Akt expression and decrease p-FoxO1 expression. To further verify the mechanism, LY294002 was used *in vitro*. The data demonstrated that following the addition of the inhibitor, low-dose LPS could not activate AKT phosphorylation and its inhibitory effect on apoptosis was also limited. The data indicated that low-dose LPS can reduce I/R-induced brain injury and prevent brain injury through the PI3K/Akt/FOXO1 signaling pathway.

In summary, LPS ameliorated morphological changes in the hippocampus, reduced inflammatory factor expression and diminished apoptosis following I/R injury. Its mechanism may be exerted through the PI3K/Akt/FoxO1 pathway, which provide a new theoretical basis for clinical treatment of I/R injury.
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![Establishment of I/R model in rats. (A) Neurological deficit scores and (B) hemodynamic changes in the control group and I/R groups. (C) TTC staining. \*P\<0.05 vs. the control group. ^\#^P\<0.05 vs. the I/R group. Hb, hemoglobin; I/R, ischemia/reperfusion; LPS, lipopolysaccharide; PaCO~2~, carbon dioxide partial pressure; PaO~2~, oxygen partial pressure; TTC, triphenyl tetrazolium chloride.](MMR-19-03-1443-g00){#f1-mmr-19-03-1443}

![LPS protects against I/R injury in rats. (A) Hematoxylin and eosin staining. (B) Neurological deficit scores following LPS treatment. \*P\<0.05 vs. the control group. ^\#^P\<0.05 vs. the I/R group. LPS, lipopolysaccharide; I/R, ischemia/reperfusion.](MMR-19-03-1443-g01){#f2-mmr-19-03-1443}

![LPS protected brain tissue from I/R injury-produced apoptosis. (A) The apoptosis of brain tissues as detected by TUNEL. Scale bar=50 µm. (B) The expression of Bcl-2, Bax and caspase-3 as detected by western blotting. (C) The expression of Bcl-2, Bax and caspase-3 as detected by reverse transcription-quantitative polymerase chain reaction. \*P\<0.05 vs. the control group; ^\#^P\<0.05 vs. I/R group. LPS, lipopolysaccharide; I/R, ischemia/reperfusion; TUNEL, terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling; Bcl-2, B-cell lymphoma 2; Bax, Bcl-2-associated X.](MMR-19-03-1443-g02){#f3-mmr-19-03-1443}

###### 

LPS inhibits neuronal apoptosis via the PI3K/Akt/FoxO1 signaling pathway following I/R injury. (A and B) Expression of PI3K, Akt, P-Akt, FoxO1 and p-FoxO1 as detected by western blotting. (C) Cell viability as detected by an MTT assay. (D) Apoptotic rate of microglia as detected by Annexin V and PI staining. (E) Apoptotic rate of microglia as detected by Annexin V and PI staining. (F and G) Akt, p-Akt, FoxO1 and p-FoxO1 as detected by western blotting. \*P\<0.05 vs. the control; ^\#^P\<0.05 vs. I/R group; \*\*P\<0.05 vs. LPS group. FoxO1, forkhead box protein O1; I/R, ischemia/reperfusion; LPS, lipopolysaccharide; LY, LY294002 (2.5 µg/kg); PI3K, phosphoinositide 3-kinase; p-, phospho-; PI, propidium iodide.

![](MMR-19-03-1443-g03)

![](MMR-19-03-1443-g04)
